Report Phase 3 clinical trial data for donanemab
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Dec 2022
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“key Phase 3 readouts, which include donanemab for early Alzheimer's disease... in 2023”
What we found
Evidence strength A What the grades mean
The company submitted donanemab for regulatory approval in 2023, confirming the Phase 3 clinical trial data was available and reported within the specified timeframe.
-
A ELI Lilly & Co 10-K filed 2024-02-21
“Submitted for approval in the U.S., the EU, and Japan in 2023.” ✓ confirmed on the page
-
A ELI Lilly & Co 8-K filed 2024-04-30
“the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab” ✓ confirmed on the page
Market reaction: the shares moved -0.4% against the S&P 500 over the three sessions around the disclosure (20 Feb 2024 to 23 Feb 2024). What this measures
Checked 4 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 clinical trial data for donanemab
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you ELI Lilly & Co? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LLY-004563 · Corrections policy